Spotlight On... Alaska Fund acquires a taste for big biotech startups; MIT spinout sets sights on PARP; Heron gets an FDA decision date; and more...

The $50 billion Alaska Permanent Fund, which handles the state's oil wealth, has invested $280 million in three biotechs: Juno ($JUNO), Denali and Codiak. And a story from Bloomberg's Doni Bloomfield notes that it works in the belief that patience is a competitive virtue when it comes to the life sciences. Interesting fact: All three startups it helped foster bear names linked to Alaska, which is far from the beaten track in biotech. Story

@FierceBiotech: Still licking Duchenne wounds, BioMarin makes an early run at Batten drug OK. More | Follow @FierceBiotech

@JohnCFierce: Syndax braves a market tempest in second IPO try, scores a $53M raise. Article | Follow @JohnCFierce

> A new MIT spinout called Ribon Therapeutics is getting off the ground with plans to raise $21 million and develop cancer drugs targeting the PARP pathway, Xconomy reports. More

> Heron Therapeutics ($HRTX) is expecting a final FDA decision on its treatment for chemotherapy-induced nausea and vomiting by early April after a pair of agency delays. News

> The head of Valeant Pharmaceuticals' ($VRX) embattled dermatology division abruptly resigned as the company faces mounting scrutiny and an SEC investigation. Story

Medical Device News

@FierceMedDev: IBM Watson unveils its first Apple ResearchKit effort with massive, patient-designed sleep study. Report | Follow @FierceMedDev

@EmilyWFierce: New York AG launches probe into insurers' coverage of hep C drugs--or lack thereof. More from FiercePharma | Follow @EmilyWFierce

> FDA approves Gore's endoprosthesis for iliac artery aneurysms. Story

> J&J Depuy does a pair of deals, one to treat disc degeneration and another for bundled payments. More

> Medtronic's disappointing earnings highlight challenge posed by currency headwinds. Article

Pharma News

@FiercePharma: Dancing bladders and football-helmeted toenails have FDA questioning cartoons in DTC ads. More from FiercePharmaMarketing | Follow @FiercePharma

@CarlyHFierce: ICYMI: Don't give up on generic Copaxone, despite Teva's aggressive brand defense: Momenta CEO. Article | Follow @CarlyHFierce

> Head of Valeant's embattled dermatology unit exits in management shakeup. Article

> Trump's healthcare plan backs drug reimportation, but leaves out Medicare price negotiation. More

> Court document accuses J&J, Bayer of keeping mum about Xarelto lab data. Item

Pharma Manufacturing News

> McKesson extends its Canada supply chain reach with $2.23B deal for Rexall chain. Report

> Another of AmerisourceBergen's Pharmedium facilities cited by FDA. Story

> Bayer spending $2.7B on capacity expansion, outgoing CEO says. Article

> Essentra adding jobs in Wales with pharma packaging facility. More

> CutisPharma adds drug manufacturing to its operations. Item

CRO News

> Infinity taps CRO Pharm-Olam for a Phase II lymphoma study. Report

> PRA eyes double-digit growth in 2016 after a banner revenue year. Story

> Chinese CRO R&G buys into Medidata's trial tech. News

> Medpace signs on to help Actinium get its cancer drug into Phase III. More

> Synexus buys Research Across America, gaining first access to the U.S. Article

Pharma Asia News

> China's Shanghai Fosun Pharmaceutical eyes RMB3B bond issue. Report

> AstraZeneca moves quickly to shed another noncore drug in ProStrakan deal. Item

> HK-based Chi-Med doses first patient in China PhII thyroid cancer trial of sulfatinib. More

> South Korea's Yuhan finds U.S. partner Sorrento for immune checkpoint antibodies JV. Story

> Americas units of Japan's Olympus hit with penalties of $623M in kickback probe. Article

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.